| Aug 28 |
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
|
| Aug 22 |
ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript
|
| Aug 22 |
Endra Life Sciences GAAP EPS of -$0.08 misses by $0.01
|
| Aug 22 |
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
|
| Aug 21 |
Endra Life Sciences Q2 2024 Earnings Preview
|
| Aug 16 |
ENDRA Life Sciences Announces Reverse Stock Split
|
| Aug 13 |
ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024
|
| Aug 13 |
ENDRA Life Sciences appoints Alexander Tokman as acting CEO
|
| Aug 13 |
ENDRA Life Sciences Announces Leadership Changes
|
| Aug 7 |
ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14
|
